ERBB2 and gastric cancer: Everolimus, an orally administered mTOR inhibitor, showed enhanced 5-FU-induced apoptosis in gastric cancer cells with HER-2 amplification and promising activity in preclinical and early clinical trials [50, 51]: such results, however, have not been confirmed in the phase III GRANITE-1 trial.